SEC Form 10-K filed by Contineum Therapeutics Inc.
$CTNM
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2026 | $14.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/13/2025 | $22.00 | Outperform | Leerink Partners |
| 9/25/2025 | $20.00 | Outperform | Leerink Partners |
| 6/20/2025 | Outperform | William Blair | |
| 10/22/2024 | $32.00 | Outperform | Robert W. Baird |
- Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026 Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones. "We're off to a strong start in 2026, having recently dosed t
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on February 17, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stock to one new non-executive employee under the Company's 2026 Employment Inducement Equity Incentive Plan. The award was granted as an inducement material to the new employee's employment with the Company in accordance with Nasda
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
S-8 - Contineum Therapeutics, Inc. (0001855175) (Filer)
424B5 - Contineum Therapeutics, Inc. (0001855175) (Filer)
10-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
Morgan Stanley downgraded Contineum Therapeutics from Overweight to Equal-Weight and set a new price target of $14.00
Leerink Partners initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $22.00
Leerink Partners initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $20.00
SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe